Results 41 to 50 of about 467,565 (384)

The Anticoagulant and Nonanticoagulant Properties of Heparin

Thrombosis and Haemostasis, 2020
Heparins represent one of the most frequently used pharmacotherapeutics. Discovered around 1926, routine clinical anticoagulant use of heparin was initiated only after the publication of several seminal papers in the early 1970s by the group of Kakkar ...
D. Beurskens, Joram P. Huckriede, R. Schrijver, H. Hemker, C. Reutelingsperger, G. Nicolaes   +5 more
semanticscholar   +1 more source

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results

Journal of Arrhythmia, 2019
Background Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on edoxaban has not been performed.
Takeshi Yamashita, Yukihiro Koretsune, Mayumi Ishikawa, Kazuhito Shiosakai, Seiji Kogure   +4 more
doaj   +1 more source

Anticoagulants [PDF]

British Medical Bulletin, 2000
Anticoagulation is a treatment with significant and life threatening complications requiring that the balance of risk and benefit be individually assessed in each patient. The risks are greater in the elderly and those with hypertension, falls and gastrointestinal disease.
openaire   +2 more sources

Pharmacogenetics of Anticoagulants [PDF]

Human Genomics and Proteomics, 2010
Warfarin, acenocoumarol, and phenprocoumon are among the major anticoagulant drugs worldwide. Because of their low therapeutic index and serious adverse reactions (ADRs), their wide use, and their varying kinetics and pharmacogenetic dependence, it is of great importance to explore further possibilities to forecast the dose beyond conventional INR ...
Anders Rane, Jonatan D. Lindh
openaire   +3 more sources

Anticoagulant interventions in hospitalized patients with COVID‐19: A scoping review of randomized controlled trials and call for international collaboration

Journal of Thrombosis and Haemostasis, 2020
Coronavirus disease (COVID‐19) is associated with a high incidence of thrombosis and mortality despite standard anticoagulant thromboprophylaxis. There is equipoise regarding the optimal dose of anticoagulant intervention in hospitalized patients with ...
T. Tritschler, M. Mathieu, L. Skeith, M. Rodger, S. Middeldorp, T. Brighton, P. Sandset, S. Kahn, D. Angus, M. Blondon, M. Bonten, M. Cattaneo, M. Cushman, L. Derde, M. Desancho, J. Diehl, E. Goligher, B. Jilma, P. Jüni, P. Lawler, M. Marietta, J. Marshall, C. McArthur, C. H. Miranda, T. Mirault, N. Morici, Usha Perepu, C. Schörgenhofer, M. Sholzberg, A. Spyropoulos, S. Webb, R. Zarychanski, S. Zuily, G. Le Gal   +33 more
semanticscholar   +1 more source

Assessment of factors affecting mortality in geriatric patients with warfarin overdose

Turkish Journal of Emergency Medicine, 2020
OBJECTIVES: The aim of the present study was to perform a demographic analysis of complications and to determine the factors affecting in-hospital mortality in geriatric patients with warfarin overdose.
Seda Dagar, Emine Emektar, Hüseyin Uzunosmanoglu, Yunsur Cevik   +3 more
doaj   +1 more source

Anticoagulant Therapy Is Associated With Decreased Long-Term Mortality in Splenic Infarction Patients: A Multicenter Study

Frontiers in Medicine, 2021
Background: Patients with splenic infarction (SI) are associated with a prothrombotic state and are vulnerable to subsequent thromboembolic complications. However, due to its rarity, there is no established treatment modality in this population. We aimed
Chieh-Ching Yen, Chieh-Ching Yen, Chih-Kai Wang, Chih-Kai Wang, Chung-Hsien Chaou, Chung-Hsien Chaou, Chung-Hsien Chaou, Shou-Yen Chen, Shou-Yen Chen, Shou-Yen Chen, Jhe-Ping Lin, Jhe-Ping Lin, Chip-Jin Ng, Chip-Jin Ng   +13 more
doaj   +1 more source

Large-scale structure of brown rat (Rattus norvegicus) populations in England: effects on rodenticide resistance [PDF]

, 2015
The brown rat (Rattus norvegicus) is a relatively recent (
Adams, Sally, Haniza, Mohd Z.H., Jones, Eleanor P., Lambert, Mark S., MacNicoll, Alan, Mallon, Eamonn B., Smith, Robert H.   +6 more
core   +2 more sources

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

British medical journal, 2019
Objectives To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years ...
F. Khan, Alvi Rahman, M. Carrier, C. Kearon, J. Weitz, S. Schulman, F. Couturaud, S. Eichinger, P. Kyrle, C. Becattini, G. Agnelli, T. Brighton, A. Lensing, M. Prins, E. Sabri, B. Hutton, L. Pinède, M. Cushman, G. Palareti, G. Wells, P. Prandoni, H. Büller, M. Rodger   +22 more
semanticscholar   +1 more source

High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia

Clinical Rheumatology, 2020
About 15–20% of patients with severe acute respiratory syndrome–coronavirus 2 (SARS-CoV2) disease experience pneumonia of variable extent and course [1]. A proportion of them have cardiovascular involvement, including myocarditis, ischemia and shock, and
C. Gazzaruso, Nicoletta Carlo Stella, G. Mariani, Carlo Nai, A. Coppola, Daniela Naldani, P. Gallotti   +6 more
semanticscholar   +1 more source